CDK9-IN-7 (compound 21e) 是一种高效选择性的，具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM)，与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡，在 G2 期阻滞细胞周期，并具有抑制非小细胞肺癌干细胞特性。

CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).

CDK9-IN-7 (compound 21e) displays exceptional potency against NSCLC cell lines, especially A549 and H1299 with IC50 values less than 0.5 μM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency (IC50: 0.837 μM)[1].

2369981-71-3

C29H37N7O2S

547.72

CDK9-IN-7

DMSO:56.7mg/mL (103.5mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years